Mckesson Stock News

The Stock-Picking Puzzle: Putting The Pieces Together

The stock price of McKesson (NYSE: MCK) increased by 3.47% in the most recent trading session. This is why it happened.

McKesson <> is trading sharply higher on Thursday after the medical distributor reported better than expected financials for the third quarter of fiscal 2021 earnings yesterday

McKesson Corp (NYSE: MCK ) reported third-quarter FY22 adjusted EPS of $6.15 , +34% Y/Y, and easily beating the analyst consensus of $5.42. Revenues increased 10% Y/Y to $68.61 billion, surpassing the consensus of $66.49 billion. U.S. Pharmaceutical segment''s Q3 FY22 revenues were $55.0 billion, +11%, driven by higher volumes from retail national Full story available on Benzinga.com

McKesson Corp MCK reported third-quarter FY22 adjusted EPS of $6.15, +34% Y/Y, and easily beating the analyst consensus of $5.42. Thousands of new traders are learning the ins and outs on how to fin

MCK earnings call for the period ending December 31, 2021.

Mckesson Corporation (MCK) shares closed 0.1% higher than its previous 52 week high, giving the company a market cap of $39B. The stock is currently up 3.4% year-to-date, up 44.3% over the past 12 months, and up 92.4% over the past five years. This week, the Dow Jones Industrial Average rose 3.2%, and the S&P 500 rose 4.3%. Trading Activity Trading volume this week was 12.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Industrials industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -594.9% The company's stock price performance over the past 12 months beats the peer average by 240.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

McKesson Earnings, Revenue Beat in Q3

McKesson Corporation (MCK) CEO Brian Tyler on Q3 2022 Results - Earnings Call Transcript

McKesson press release (MCK): Q3 Non-GAAP EPS of $6.15 beats by $0.73.Revenue of $68.6B (+9.6% Y/Y) beats by $1.97B.Increased fiscal 2022 Adjusted Earnings per Diluted Share

PLANO, Texas, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Center for Autism and Related Disorders ( CARD ®; centerforautism.com) , today announced senior leadership changes that further position the organization to deliver high-quality patient care, strong financial performance, and operational excellence as the world''s largest Autism treatment provider. CARD is pleased to announce that effective immediately, Jennifer Webster has been named Chief Executive Officer . Webster will oversee CARD''s full business portfolio, focusing on optimizing CARD''s national network of centers, expanding reach to new markets, and ensuring quality of care for patients and families. Webster is a highly accomplished senior finance executive with over 25 years of leadership experience with Fortune 50 companies McKesson and General Electric. She has served as CARD''s Chief Financial Officer for the last three years and replaces Tony Kilgore, Full story available on Benzinga.com

McKesson (MCK) delivered earnings and revenue surprises of 14.31% and 3.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (NYSE: JNJ ) and the three U.S. drug distributors agreed to pay about $590 million to resolve claims from over 400 Native American tribes to settle lawsuits over the opioid epidemic. That proposed settlement, though, did not resolve lawsuits and potential claims by the country''s 574 federally recognized Native American tribes and Alaska Native villages, which experienced disproportionately high rates of opioid overdoses. The deal came after the distributors, McKesson Corporation (NYSE: Full story available on Benzinga.com

By Manojna Maddipatla (Reuters) McKesson Corp is expected to report strong earnings on Wednesday as an Omicron-driven surge in demand for COVID-19 vaccines and tests is likely to insulate the drug distributor from tepid sales of other medical products.